中国企业去年进行了全球近三分之一的临床试验，高于十年前的6%，确立了中国作为第二大新药来源国的地位。此外，2025年价值5000万美元或以上的许可交易中，近一半是与中国企业达成的，而2020年这一比例为零。

中国还占有重要药物中70%以上的活性药物成分。由于将一种新药推向市场需要花费约28亿美元且耗时十多年，因此拒绝来自中国的临床试验数据将进一步损害研发效率并延迟挽救生命的疗法。

美国政策制定者不应通过投资禁令或忽视临床数据来限制中国生物技术，而应专注于解决国内问题，如食品药品监督管理局（FDA）的人员流失和国家卫生研究院的资金削减。促进科学合作而非保护主义，对于确保全球患者获得负担得起且有效的治疗至关重要。

Chinese firms ran nearly a third of the world's clinical trials last year, up from 6% a decade ago, establishing China as the second-largest source of new drugs. Additionally, nearly half of all licensing deals worth $50 million or more in 2025 were struck with Chinese firms, compared to none in 2020.

China also accounts for over 70% of the active pharmaceutical ingredients for essential drugs. Since bringing a new medicine to market costs approximately $2.8 billion and takes over a decade, rejecting Chinese clinical-trial data would further damage productivity and delay lifesaving treatments.

Rather than restricting Chinese biotechnology through investment bans or disregarding clinical data, American policymakers should focus on addressing domestic issues such as FDA turnover and funding cuts for the National Institutes of Health. Fostering scientific collaboration, rather than protectionism, is crucial to ensuring global patients receive affordable and effective treatments.

Source: Don’t restrict Chinese biotech

Subtitle: Patients benefit from faster, cheaper treatments, wherever they are invented

Dateline: 6月 18, 2026 03:46 上午